#EAU20 Virtual - Radioligand therapy in metastatic castration-resistant prostate cancer
Time Zone:
Europe/Madrid GMT+2
Institution:
EAU
previous registration necessary?
NO
YES
Simultaneous translation ?
NO
YES
Will it be recorded?
NO
YES
Moderator:
Speakers:
Theme :
Language:
A. Briganti, M. Heck, D. Murphy
M. Gauthé, P. Rescigno, T. Steuber, I. Tsaur, UV Vogl, M. Eiber, A. Heidenreich
Current and future radioligands (ligands and emitters)
Inglês
Radioligand therapy in metastatic castration-resistant prostate cancer
Thematic session 04
Fri 17 July
18:30 - 20:00
Location:Virtual room 2Chairs: A. Briganti, Milan (IT)
M. Heck, Munich (DE)
D. Murphy, Melbourne (AU)
Learning objectives
Prostate-specific membrane antigen (PSMA) offers great potential not only as a target for diagnostic but also for therapeutic purposes. The present session highlights the application of PSMA-targeted radioligand therapy in metastatic castration-resistant prostate cancer. Indication, limitations and future developments will be discussed.
18:30 - 18:45
Current and future radioligands (ligands and emitters)
M. Gauthé, Paris (FR)
18:45 - 19:00
Limitations of PSMA based on prostate cancer biology
P. Rescigno, London (GB)
19:00 - 19:15
Critical assessment of radioligand therapy
T. Steuber, Hamburg (DE)
19:15 - 19:50
Case-based debate (PSMA)-targeted radioligand therapy: For which patients, which stages?
19:15 - 19:20
Case presentation
I. Tsaur, Mainz (DE)
19:20 - 19:30
Treatment options: Medical oncologist
UV Vogl, Bellinzona (CH)
19:30 - 19:40
Treatment options: Nuclear medicine
M. Eiber, Munich (DE)
19:40 - 19:50
Radioligand therapy for less advanced cases: Urologist
A. Heidenreich, Cologne (DE)
19:50 - 20:00
Discussion, questions and answers
A. Briganti, Milan (IT)
M. Heck, Munich (DE)
D. Murphy, Melbourne (AU)